Harmony Biosciences (HRMY) News Today $32.79 +0.31 (+0.95%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Quest Partners LLC Acquires 20,689 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Quest Partners LLC boosted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 137.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 35,723 shares of the company's stock after purchasingNovember 20 at 4:45 AM | marketbeat.comPrincipal Financial Group Inc. Sells 19,654 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Principal Financial Group Inc. decreased its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 10.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 162,469 sharesNovember 20 at 3:08 AM | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Short Interest Down 18.7% in OctoberHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) was the recipient of a significant decline in short interest in October. As of October 31st, there was short interest totalling 6,060,000 shares, a decline of 18.7% from the October 15th total of 7,450,000 shares. Approximately 15.2% of the company's stock are short sold. Based on an average daily volume of 683,700 shares, the short-interest ratio is currently 8.9 days.November 17, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of "Moderate Buy" by BrokeragesNovember 13, 2024 | americanbankingnews.comHead-To-Head Analysis: Psyence Biomedical (NASDAQ:PBM) & Harmony Biosciences (NASDAQ:HRMY)November 12, 2024 | americanbankingnews.comCWA Asset Management Group LLC Purchases New Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)CWA Asset Management Group LLC acquired a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 14,396 shares of the company's stock, valued at approximately $576,000. OtherNovember 12, 2024 | marketbeat.comHarmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection PointsNovember 11, 2024 | seekingalpha.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Average Rating of "Moderate Buy" from AnalystsShares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine ratings firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and seven haveNovember 8, 2024 | marketbeat.comHarmony Biosciences Holdings: Strong Growth Potential and Attractive Valuation Amidst Robust Product PipelineNovember 5, 2024 | markets.businessinsider.comHarmony Biosciences Reports Record Revenue and Plans Expansion in CNS TreatmentsNovember 5, 2024 | msn.comAlphaCentric Advisors LLC Reduces Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)AlphaCentric Advisors LLC decreased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 20.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 97,000 shares of the companyNovember 5, 2024 | marketbeat.comEarnings Beat: Harmony Biosciences Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsNovember 2, 2024 | finance.yahoo.comHarmony Biosciences price target raised to $59 from $56 at OppenheimerNovember 1, 2024 | markets.businessinsider.comWhy Harmony Biosciences (HRMY) Stock Is Down 18% TodayNovember 1, 2024 | benzinga.comUpdate: HRMY, MGPI and OTEX, October 29November 1, 2024 | forbes.comJeffrey Dierks Sells 21,496 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) StockNovember 1, 2024 | insidertrades.comHarmony Biosciences (NASDAQ:HRMY) Sees Strong Trading Volume Following Analyst UpgradeHarmony Biosciences (NASDAQ:HRMY) Sees Strong Trading Volume After Analyst UpgradeOctober 31, 2024 | marketbeat.comHRMY FY2024 EPS Estimate Raised by Cantor FitzgeraldHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Cantor Fitzgerald upped their FY2024 earnings estimates for shares of Harmony Biosciences in a research report issued to clients and investors on Wednesday, October 30th. Cantor Fitzgerald analyst C. Duncan now expects that the compOctober 31, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling ShareholdersOctober 30, 2024 | prnewswire.comHarmony Biosciences (NASDAQ:HRMY) Price Target Raised to $58.00 at Cantor FitzgeraldCantor Fitzgerald raised their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the company an "overweight" rating in a research note on Wednesday.October 30, 2024 | marketbeat.comHarmony Biosciences: Strong Q3 and Future GrowthOctober 30, 2024 | markets.businessinsider.comCantor Fitzgerald Sticks to Its Buy Rating for Harmony Biosciences Holdings (HRMY)October 30, 2024 | markets.businessinsider.comHarmony Biosciences Holdings Inc (HRMY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth ...October 30, 2024 | finance.yahoo.comHarmony Biosciences (NASDAQ:HRMY) Given "Outperform" Rating at OppenheimerOppenheimer restated an "outperform" rating and set a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a report on Wednesday.October 30, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Announces Quarterly Earnings Results, Beats Expectations By $0.15 EPSHarmony Biosciences (NASDAQ:HRMY - Get Free Report) issued its earnings results on Tuesday. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The company had revenue of $186.00 million for the quarter, compared to analysts' expectations of $184.07 million. During the same period in the prior year, the business earned $0.63 EPS. The firm's quarterly revenue was up 16.0% on a year-over-year basis.October 30, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Shares Gap Down - What's Next?Harmony Biosciences (NASDAQ:HRMY) Shares Gap Down - Here's What HappenedOctober 30, 2024 | marketbeat.comHarmony Biosciences Holdings: Strong Financials and Strategic Advancements Reinforce Buy RatingOctober 30, 2024 | markets.businessinsider.comHarmony Biosciences announces 8M share offering of common stock for holdersOctober 30, 2024 | markets.businessinsider.comHarmony Biosciences (NASDAQ:HRMY) Stock, Insider Trading ActivityOctober 29, 2024 | benzinga.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Large Decrease in Short InterestHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totalling 7,450,000 shares, a decrease of 12.8% from the September 30th total of 8,540,000 shares. Currently, 24.3% of the shares of the stock are short sold. Based on an average daily volume of 441,800 shares, the short-interest ratio is presently 16.9 days.October 29, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling ShareholdersOctober 29, 2024 | prnewswire.comHarmony Biosciences Holdings, Inc. (HRMY) Q3 2024 Earnings Call TranscriptOctober 29, 2024 | seekingalpha.comHarmony Biosciences Holdings, Inc Q3 Profit Increases, Beats EstimatesOctober 29, 2024 | markets.businessinsider.comUpdate: HRMY, October 29October 29, 2024 | msn.comHarmony Biosciences (HRMY) Q3 2024 Earnings Call TranscriptOctober 29, 2024 | msn.comHarmony Biosciences Holdings, Inc. 2024 Q3 - Results - Earnings Call PresentationOctober 29, 2024 | seekingalpha.comHarmony Biosciences (NASDAQ:HRMY) Shares Gap Up - Here's What HappenedHarmony Biosciences (NASDAQ:HRMY) Shares Gap Up - Here's What HappenedOctober 29, 2024 | marketbeat.comHarmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' BeatOctober 29, 2024 | investors.comNeedham & Company LLC Reaffirms "Buy" Rating for Harmony Biosciences (NASDAQ:HRMY)Needham & Company LLC reaffirmed a "buy" rating and set a $52.00 price target on shares of Harmony Biosciences in a report on Tuesday.October 29, 2024 | marketbeat.comHarmony Biosciences Q3 2024 Earnings PreviewOctober 28, 2024 | msn.comGet Ready for Harmony Biosciences’ Q3 2024 Financial ResultsOctober 20, 2024 | msn.comStrategic Positioning and Growth Potential in Harmony Biosciences’ Epilepsy Market VentureOctober 18, 2024 | markets.businessinsider.comHARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024October 16, 2024 | prnewswire.comWall Street Analysts Favor Harmony Biosciences Holdings, Inc. (HRMY) for GrowthOctober 14, 2024 | msn.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation and seven haveOctober 14, 2024 | marketbeat.comLivforsakringsbolaget Skandia Omsesidigt Has $1.80 Million Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Livforsakringsbolaget Skandia Omsesidigt increased its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 84.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,900 shares of the company's stock after buying an additioOctober 13, 2024 | marketbeat.comIs Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) The Top Stock With Improving Technical Ratings According To Piper Sandler?October 12, 2024 | msn.comHarmony Biosciences Holdings Inc (HRMY) Q2 2024 Earnings Call Highlights: Strong Revenue Growth ...October 10, 2024 | finance.yahoo.comHarmony Biosciences (NASDAQ:HRMY) Given "Outperform" Rating at Raymond JamesRaymond James reissued an "outperform" rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday.October 10, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) PT Raised to $52.00 at MizuhoMizuho increased their price objective on Harmony Biosciences from $42.00 to $52.00 and gave the stock an "outperform" rating in a report on Thursday.October 10, 2024 | marketbeat.com Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. HRMY Media Mentions By Week HRMY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HRMY News Sentiment▼0.570.45▲Average Medical News Sentiment HRMY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HRMY Articles This Week▼34▲HRMY Articles Average Week Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Xencor News Taro Pharmaceutical Industries News OPKO Health News Zymeworks News Prelude Therapeutics News Axsome Therapeutics News Corcept Therapeutics News Legend Biotech News Elanco Animal Health News Blueprint Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HRMY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HRMY Stock Alerts